SGX Pharmaceuticals is building an internal oncology product pipeline through the application of our proprietary fragment-based drug discovery platform, Fragments of Active Structures (FAST). We have successfully applied FAST to generate novel, potent and selective small molecule compounds in a matter of months for many well-validated but challenging targets.

We are taking a targeted approach to the discovery and development of innovative therapeutic agents by seeking to identify small molecules that selectively block or inhibit the actions of proteins responsible, either wholly or in part, for the uncontrolled growth of malignant cells in human cancers.

Generally, we have selected drug discovery and development targets for which there is strong scientific evidence that DNA abnormalities activate the target protein and in turn lead to uncontrolled cellular growth and replication. Uncontrolled cellular growth and replication are both typically associated with cancer.

Our strategy for the further development of such targeted inhibitors is to design and execute initial clinical trials involving patients who are selected on the basis of strong scientific evidence of the requisite activating DNA abnormality. We believe this targeted approach increases the potential for demonstrating clinical benefit, and potentially decreases the time required to conduct the clinical study, reducing the number of patients enrolled in a clinical study, and reducing the cost of the clinical study as compared to conventional more inclusive large-scale clinical trials.

We have selected indications for which we believe there are clear recognized unmet medical needs that could reduce the time required to obtain necessary regulatory approvals. Our drug discovery and development strategy aims to produce new chemical entities with substantial commercial potential resulting from selective inactivation of validated targets in cancer patients likely to experience clinical benefit.